Fundraising Fox
Ideaya Biosciences
NASDAQ: IDYASouth San Francisco, US · Founded 2015 · Delaware corporation · 281 employees on LinkedIn · 7 known investors
Find your way into Ideaya Biosciences
Sign up to see every warm intro you have to Ideaya Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ideaya Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
Founders & leadership
Board
Investors · 7
How we know: 5AM Ventures's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Canaan Partners's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Nextech Invest's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Roche Venture Fund's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$111.4M disclosed across 2 rounds · 2016–2018
▶$94MraisedMay 2018 · 23 investors · BiotechnologyRule 506(b)
- Paul A. StoneExecutive Officer
- Yujiro S. HataDirector, Executive Officer
- Jeffrey HagerExecutive Officer
- Edward HuDirector
- Jeffrey SteinDirector
- Terry RosenDirector
- John D. DiekmanDirector
- Brian DanielsDirector
- Timothy ShannonDirector
- Tim SmithExecutive Officer
- Thilo SchroederDirector
- Michael P. DillonExecutive Officer
- Offering amount
- $94M
- Amount sold
- $94M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$17.4MraisedAug 2016 · 10 investors · OtherRule 506(b)
- Paul StoneExecutive Officer
- Yujiro HataExecutive Officer, Director
- Timothy ShannonDirector
- Terry RosenDirector
- Jeffrey SteinDirector
- John DiekmanDirector
- Offering amount
- $46.2M
- Amount sold
- $17.4M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 2
Companies working in the same space as Ideaya Biosciences.
Frequently asked questions
- What does Ideaya Biosciences do?
- IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
- Who are Ideaya Biosciences's investors?
- Ideaya Biosciences's investors include 5AM Ventures, Canaan Partners, GV (Google Ventures), Nextech Invest, Roche Venture Fund, Biotechnology Value Fund, WuXi Healthcare Ventures.
- How much funding has Ideaya Biosciences raised?
- Ideaya Biosciences has disclosed $111.4M raised across 2 rounds.
- Where is Ideaya Biosciences headquartered?
- Ideaya Biosciences is headquartered in South San Francisco, US.